GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (STU:1S1) » Definitions » 5-Year Yield-on-Cost %

Viridian Therapeutics (STU:1S1) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 12, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Viridian Therapeutics 5-Year Yield-on-Cost %?

Viridian Therapeutics's yield on cost for the quarter that ended in Dec. 2024 was 0.00.


The historical rank and industry rank for Viridian Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



STU:1S1's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.74
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Viridian Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Viridian Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viridian Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's 5-Year Yield-on-Cost % falls into.


;
;

Viridian Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Viridian Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Viridian Therapeutics  (STU:1S1) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Viridian Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Viridian Therapeutics Business Description

Traded in Other Exchanges
Address
221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics Headlines

No Headlines